Company record · DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences, Inc.
Precision BioSciences, Inc.'s chief financial officer on the record is Naresh Tanna, effective August 1, 2026, per the filing record.
The record holds 1 verified CFO change for Precision BioSciences, Inc. from Form 8-K filings, filed July 27, 2026 and the CFO signature on its 10-K filed March 12, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Naresh Tanna |
| Title as printed | Chief Financial Officer |
| Basis | Latest move: transition, 8-K filed July 27, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-07-27Transition
Precision BioSciences, Inc. CFO transition: Naresh Tanna to succeed Alex Kellyeffective August 1, 2026 · 8-K filed July 27, 2026 · sec.gov, Item 5.02
2026-03-1210-K signature
John Alexander Kelly signed the annual report as Chief Financial Officer (principal financial and accounting officer)
10-K filed March 12, 2026 · sec.gov
“/s/ John Alexander Kelly John Alexander Kelly Chief Financial Officer (principal financial and accounting officer)”
Company
| Ticker | DTIL |
|---|---|
| SEC CIK | 0001357874 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | The DEF 14A filed 2026-04-08 does not name John Alexander Kelly near a Chief Financial Officer title; check for a change. An 8-K with Item 5.02 was filed on 2026-07-27, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Departure disclosed · Geoffrey Parker · no successor on the record yet
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.